Register Now: Beyond EDC: Designing a Connected Data Strategy for Predictive Clinical Development

Publication|Videos|July 18, 2024

PurpleLab Accelerates Clinical Trial Lifecycle with Real-World-Data

Author(s)PurpleLab

Jason Gagner (Vice President of Product for Life Science, PurpleLab) talks about clinical trial variables and how PurpleLab is working to maintain patient retention and accelerate site feasibility.

Approximately 80% of clinical trials will face delays at some point in the trial process. Jason Gagner talked with ACT about how PurpleLab uses real-world data to better inform trials and improve their success rates.

Learn More About:

Utilizing real-world data (RWD) to assist clinical trials achieve key milestones
Employing a criteria specific geographic analysis of patient populations to expedite site feasibility assessments
Understanding the impact of diversity, equity, and inclusion (DEI) in clinical trials on meeting trial objectives and timelines
Integrating social determinants of health (SDOH) data to minimize patient dropout rates

Newsletter

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Related to this article

Embedding AI Across the Clinical Operating Model: Q&A with Rajneesh Patil, Syneos Health

November 2nd, 2026

Embedding AI Across the Clinical Operating Model: Q&A with Rajneesh Patil, Syneos Health

In this Q&A, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, discusses what changes when AI is embedded across protocol strategy, data infrastructure, and workflow tools at once, where governance frameworks tend to fall short, and why CROs must orchestrate AI ecosystems rather than simply aggregate them.

ACT Brief: Community Research Policy Needs, Walmart Trial Centers, and Psoriatic Arthritis Approval

November 2nd, 2026

ACT Brief: Community Research Policy Needs, Walmart Trial Centers, and Psoriatic Arthritis Approval

In today’s ACT Brief, we examine what policy changes would help community and rural institutions join research, how Walmart is expanding clinical trial centers into three more states, and how FDA approved Ilumya for adults with active psoriatic arthritis.

© peshkova - © peshkova - stock.adobe.com

October 30th, 2026

Walmart and Care Access Plan Three More Clinical Trial Centers in Michigan, Nevada, and Texas

The planned sites in Livonia, Las Vegas, and San Antonio would expand a partnership that places clinical research and health screenings inside Walmart stores.

What Needs to Happen Beyond the Clinical Trial Modernization Act

October 30th, 2026

What Needs to Happen Beyond the Clinical Trial Modernization Act

In this video interview, Kent Thoelke, CEO of Paradigm Health, calls for safe harbor protections, CMS reimbursement safeguards, and funding mechanisms modeled on EHR meaningful use to help community and rural institutions participate in research on par with academic centers.

ACT Brief: Community Research Access, Trustworthy AI Assistants, and Individualized Gene Editing Guidance

October 30th, 2026

ACT Brief: Community Research Access, Trustworthy AI Assistants, and Individualized Gene Editing Guidance

In today’s ACT Brief, we examine why community and rural patients lack access to research as a care option, what makes AI assistants trustworthy in regulated trials, and how FDA draft guidance could let gene editing therapies cover patient-specific variants.

Building AI Assistants Clinical Trial Teams Can Trust: Q&A with E.K. Koh, Suvoda

October 29th, 2026

Building AI Assistants Clinical Trial Teams Can Trust: Q&A with E.K. Koh, Suvoda

In this Q&A, E.K. Koh, chief product officer at Suvoda, discusses what separates a trustworthy AI assistant from one that adds risk, why curated clinical knowledge matters more than general-purpose flexibility, and what safeguards must be in place when assistants move from answering questions to taking actions in clinical trial systems.

How Embedding Research Into Routine Community Care Changes Who Gets Access

October 29th, 2026

How Embedding Research Into Routine Community Care Changes Who Gets Access

In this video interview, Kent Thoelke, CEO of Paradigm Health, explains why patients in community and rural settings too often lack access to clinical research as a care option, and how closing that gap could improve outcomes and lower long-term costs.

ACT Brief: Community Trial Access Technology, RBQM Infrastructure, and Digital Clone Use Cases

October 29th, 2026

ACT Brief: Community Trial Access Technology, RBQM Infrastructure, and Digital Clone Use Cases

In today’s ACT Brief, we examine why anti-kickback guidance and EHR-integrated trial matching must work together in community settings, why real-time trials depend on mature risk-based quality management, and how pharma is applying digital clones to predict outcomes.

Trending on Applied Clinical Trials Online

What Needs to Happen Beyond the Clinical Trial Modernization Act

Building AI Assistants Clinical Trial Teams Can Trust: Q&A with E.K. Koh, Suvoda

Walmart and Care Access Plan Three More Clinical Trial Centers in Michigan, Nevada, and Texas

Real-Time Continuous Trials Through the Lens of Risk-Based Quality Management: Why RBQM Is the Infrastructure RTCT Cannot Exist Without

ACT Brief: Community Research Access, Trustworthy AI Assistants, and Individualized Gene Editing Guidance